biotech · Post Traumatic Stress Disorder · Prosthetic Joint Infection · ADPT
Adaptive Biotechnologies
Adaptive Biotechnologies Corp
Adaptive Biotechnologies is a biotech organization headquartered in Seattle, USA. It trades on NYSE under ticker ADPT. Primary therapeutic focus areas include Post Traumatic Stress Disorder, Prosthetic Joint Infection, O
1165 Eastlake Ave E, Seattle, Washington 98109, US HQ
2009 Founded
659 Employees
Public company Type
ADPT · NYSE Ticker
Company details
- Status
- Public
- HQ
- 1165 Eastlake Ave E, Seattle, Washington 98109, US
- Founded
- 2009
- Employees
- 659
- Programs
- 19
- Drugs
- 23
- Patents
- 12
Mosunetuzumab
Phase 2 · small molecule · Diffuse Large B-Cell Lymphoma (DLBCL)
Mosunetuzumab for Diffuse Large B-Cell Lymphoma (DLBCL) is a Phase 2 program (small_molecule) at Adaptive Biotechnologies Corp with 1 ClinicalTrials.gov record(s).
Internal code UMLYM24067
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Adaptive Biotechnologies Corp
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Diffuse Large B-Cell Lymphoma (DLBCL)
- Status
- active
- Trials
- 1